← Feed

$COST

3 theses
bullish 33%neutral 0%bearish 67%
Avg return (3d)
+0.4%
Win rate (3d)
100% (1 resolved)
1d3d1w1m3m6m1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 18, 4:30 PM ET
$COSTSEC Form 4bearish
Frates Caton · Sr. Executive Vice President at COSTCO WHOLESALE CORP /NEW · 5h agono track record yet
Sold 801 @ $915.93 avg · $733,328 · 2026-09-29

Form 4: Frates Caton sold COST

Frates Caton (Sr. Executive Vice President at COSTCO WHOLESALE CORP /NEW) reported an open-market sale of 800.64 shares of COST at an average $915.93, roughly $733,328, in a Form 4 filed 2026-09-30.

Now $895.31as of Sep 18, 4:30 PM ET
View filing on SEC.gov →
$COSTSEC Form 4bearish
Adamo Claudine · Executive Vice President at COSTCO WHOLESALE CORP /NEW · 5h agono track record yet
Sold 2,200 @ $915.93 avg · $2,015,046 · 2026-09-29

Form 4: Adamo Claudine sold COST

Adamo Claudine (Executive Vice President at COSTCO WHOLESALE CORP /NEW) reported an open-market sale of 2,200 shares of COST at an average $915.93, roughly $2,015,046, in a Form 4 filed 2026-09-30.

Now $895.31as of Sep 18, 4:30 PM ET
View filing on SEC.gov →
$COSTr/ValueInvestingDiscussionbullish
u/snapjohn · 361d ago5 prior · awaiting results

$COST now selling Ozempic for $499 after partnering with $NVO

Costco's partnership with Novo Nordisk to sell Ozempic and Wegovy at $499/month could strengthen the pharmacy business (growing ~15% y/y) and membership moat by adding a popular healthcare offering that increases renewal rates and average member spend, even if near-term EPS impact is modest.

At post $905.66Now $895.31-1.1% since postedas of Sep 18, 4:30 PM ET
1d—
3d+0.4%
1w+2.1%
1m+2.0%
3m-6.1%
6m+11.7%
1y—
original post →

End of results.